Polaramine 5 mg/ml solución inyectable

A multicenter, open-label, non-comparative, single-arm, phase II trial of datopotamab deruxtecan for non-squamous non-small cell lung cancer patients with active brain metastases (The TUXEDO-5 Study)

MorningLyte: A Phase III randomized, open-label, international, multicenter study evaluating the efficacy and safety of mosunetuzumab plus lenalidomide in comparison to anti-CD20 monoclonal antibody plus chemotherapy in subjects with previously untreated FLIPI 2-5 follicular lymphoma